NEUROBO PHARMACEUTICALS INC(NASDAQ:NRBO) stock News

NRBO Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

a year ago - By: Virtual Investor Conferences - Mentions: MRVL.CA CGTX ZVSA DRMA

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

a year ago - By: Virtual Investor Conferences - Mentions: ZVSA DRMA CGTX

Life Sciences Investor Forum Agenda Announced for November 14th

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

a year ago - By: Benzinga - Mentions: NVAX ASMB NVCR ABVC ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: BusinessInsider

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

a year ago - By: InvestorPlace

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

a year ago - By: Benzinga - Mentions: NANX NUVB

NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

2 years ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

2 years ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

a year ago - By: InvestorPlace

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024

a year ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

2 years ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

2 years ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

2 years ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

2 years ago - By: Seeking Alpha - Mentions: LLY NVO

NeuroBo stock jumps 14% on weight-loss drug update (NASDAQ:NRBO)

2 years ago - By: NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

2 years ago - By: InvestorPlace - Mentions: NYCB SBNY PTON MCO ...

NEUROBO PHARMACEUTICALS INC (NRBO) Stock News

NRBO Latest News, Press Relases and Analysis

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Life Sciences Investor Forum Agenda Announced for November 14th

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

NeuroBo stock jumps 14% on weight-loss drug update (NASDAQ:NRBO)

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

The Top 3 Stocks to Watch This Week